Last reviewed · How we verify
SHC014748M
At a glance
| Generic name | SHC014748M |
|---|---|
| Sponsor | Nanjing Sanhome Pharmaceutical, Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma (PHASE2)
- A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PHASE2)
- A Food-Effect Study of SHC014748M in Healthy Subjects (PHASE1)
- Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHC014748M CI brief — competitive landscape report
- SHC014748M updates RSS · CI watch RSS
- Nanjing Sanhome Pharmaceutical, Co., Ltd. portfolio CI